Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : TAK crawled date : 2022 - 05 - 03 save search
Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Published: 2022-05-03 (Crawled : 18:00) - biospace.com/
TAK | $13.15 -0.61% 0.38% 1.7K
|
Health Technology
|
| O: 0.41%
H: 0.0%
C: 0.0%
BMY | $47.84 370K
|
Health Technology
|
| O: 0.36%
H: 0.0%
C: 0.0%
EXEL | $22.87 0.22% 0.24% 210
|
Health Technology
|
| O: 0.09%
H: 1.54%
C: -0.44%
cabometyx approval cancer
Ipsen: European Commission Approves Cabometyx® as a Second-Line Treatment for People Living With Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Published: 2022-05-03 (Crawled : 08:00) - biospace.com/
TAK | $13.15 -0.61% 0.38% 1.7K
|
Health Technology
|
| O: 0.41%
H: 0.0%
C: 0.0%
cabometyx treatment cancer
Gainers vs Losers
| 48% | 52% |
Top 10 Gainers
AGBA | $1.44 260.0% 40M
|
Finance
BPTH | $6.25 92.9% 20M
|
Health Technology
EGOX | $0.0447 39.25% 24M
|
BNTC | $5.91 23.13% 1.3M
|
Health Technology
XPON | $2.33 20.73% 410K
|
BRSH | $0.0515 15.99% 12M
|
n/a
VTNR S | $1.12 14.38% 470K
|
Industrial Services
DXYZ 4 | $33.49 13.41% 210K
|
n/a
BMI 4 | $169.84 11.01% 68K
|
Producer Manufacturing
CTM | $0.244 10.86% 40K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.